{"id":"https://openalex.org/W3133482751","doi":"https://doi.org/10.1158/1538-7445.sabcs20-ps17-11","title":"Abstract PS17-11: Her2-xpat, a novel protease-activatable prodrug t-cell engager (tce), exhibits potent t-cell activation and efficacy in her2 tumors, yielding large predicted safety margins based on non-human primate (nhp)","display_name":"Abstract PS17-11: Her2-xpat, a novel protease-activatable prodrug t-cell engager (tce), exhibits potent t-cell activation and efficacy in her2 tumors, yielding large predicted safety margins based on non-human primate (nhp)","publication_year":2021,"publication_date":"2021-02-15","ids":{"openalex":"https://openalex.org/W3133482751","doi":"https://doi.org/10.1158/1538-7445.sabcs20-ps17-11","mag":"3133482751"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.sabcs20-ps17-11","doi":"https://doi.org/10.1158/1538-7445.sabcs20-ps17-11","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs20-ps17-11","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5033675619","display_name":"Fiore Cattaruzza","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210131535","display_name":"Amunix (United States)","ror":"https://ror.org/037sxey58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210131535"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Fiore Cattaruzza","raw_affiliation_strings":["Amunix, Mountain View, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amunix, Mountain View, CA","institution_ids":["https://openalex.org/I4210131535"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111147020","display_name":"Ayesha Nazeer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210131535","display_name":"Amunix (United States)","ror":"https://ror.org/037sxey58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210131535"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ayesha Nazeer","raw_affiliation_strings":["Amunix, Mountain View, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amunix, Mountain View, CA","institution_ids":["https://openalex.org/I4210131535"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051527877","display_name":"Zachary Lange","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210131535","display_name":"Amunix (United States)","ror":"https://ror.org/037sxey58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210131535"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Zachary Lange","raw_affiliation_strings":["Amunix, Mountain View, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amunix, Mountain View, CA","institution_ids":["https://openalex.org/I4210131535"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059098189","display_name":"Caitlin Koski","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210131535","display_name":"Amunix (United States)","ror":"https://ror.org/037sxey58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210131535"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Caitlin Koski","raw_affiliation_strings":["Amunix, Mountain View, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amunix, Mountain View, CA","institution_ids":["https://openalex.org/I4210131535"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071941321","display_name":"Mikhail Hammond","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210131535","display_name":"Amunix (United States)","ror":"https://ror.org/037sxey58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210131535"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mikhail Hammond","raw_affiliation_strings":["Amunix, Mountain View, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amunix, Mountain View, CA","institution_ids":["https://openalex.org/I4210131535"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026185277","display_name":"Angela Henkensiefken","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210131535","display_name":"Amunix (United States)","ror":"https://ror.org/037sxey58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210131535"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Angela Henkensiefken","raw_affiliation_strings":["Amunix, Mountain View, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amunix, Mountain View, CA","institution_ids":["https://openalex.org/I4210131535"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054997551","display_name":"Trang Dao-Pick","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210131535","display_name":"Amunix (United States)","ror":"https://ror.org/037sxey58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210131535"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Trang Dao-Pick","raw_affiliation_strings":["Amunix, Mountain View, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amunix, Mountain View, CA","institution_ids":["https://openalex.org/I4210131535"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049851359","display_name":"Mika Kakefuda Derynck","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210131535","display_name":"Amunix (United States)","ror":"https://ror.org/037sxey58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210131535"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mika K Derynck","raw_affiliation_strings":["Amunix, Mountain View, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amunix, Mountain View, CA","institution_ids":["https://openalex.org/I4210131535"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030418854","display_name":"Bryan A. Irving","orcid":"https://orcid.org/0000-0002-5093-013X","observed_orcids":["https://orcid.org/0000-0002-5093-013X"]},"institutions":[{"id":"https://openalex.org/I4210131535","display_name":"Amunix (United States)","ror":"https://ror.org/037sxey58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210131535"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bryan Irving","raw_affiliation_strings":["Amunix, Mountain View, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amunix, Mountain View, CA","institution_ids":["https://openalex.org/I4210131535"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5018783910","display_name":"Volker Schellenberger","orcid":"https://orcid.org/0000-0002-3491-8229","observed_orcids":["https://orcid.org/0000-0002-3491-8229"]},"institutions":[{"id":"https://openalex.org/I4210131535","display_name":"Amunix (United States)","ror":"https://ror.org/037sxey58","country_code":"US","type":"company","lineage":["https://openalex.org/I4210131535"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Volker Schellenberger","raw_affiliation_strings":["Amunix, Mountain View, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amunix, Mountain View, CA","institution_ids":["https://openalex.org/I4210131535"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210131535"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"81","issue":"4_Supplement","first_page":"PS17","last_page":"11"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.5752000212669373,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.5752000212669373,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.11949999630451202,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.0771000012755394,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/t-cell-engagers","display_name":"T-cell engagers","score":0.902999997138977},{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.7179999947547913},{"id":"https://openalex.org/keywords/hormone-receptor-positive-breast-cancer","display_name":"hormone receptor-positive breast cancer","score":0.734000027179718},{"id":"https://openalex.org/keywords/t-cell-mediated-cytotoxicity","display_name":"T cell cytotoxicity","score":0.7799999713897705},{"id":"https://openalex.org/keywords/therapeutic-index","display_name":"therapeutic index","score":0.5820000171661377},{"id":"https://openalex.org/keywords/non-human-primate-safety","display_name":"non-human primate safety","score":0.7570000290870667},{"id":"https://openalex.org/keywords/on-target-off-tumor-toxicity","display_name":"on-target off-tumor toxicity","score":0.7710000276565552},{"id":"https://openalex.org/keywords/xenograft-models","display_name":"xenograft models","score":0.6119999885559082},{"id":"https://openalex.org/keywords/mcf-7-cells","display_name":"MCF-7 cells","score":0.640999972820282},{"id":"https://openalex.org/keywords/her2-low-tumors","display_name":"HER2-low tumors","score":0.3149999976158142}],"concepts":[{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6395514011383057},{"id":"https://openalex.org/C108215921","wikidata":"https://www.wikidata.org/wiki/Q603741","display_name":"Prodrug","level":2,"score":0.5532561540603638},{"id":"https://openalex.org/C2776714187","wikidata":"https://www.wikidata.org/wiki/Q212410","display_name":"Protease","level":3,"score":0.5336576104164124},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.45656949281692505},{"id":"https://openalex.org/C2776107976","wikidata":"https://www.wikidata.org/wiki/Q1786433","display_name":"Tumor microenvironment","level":3,"score":0.453225702047348},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.4410875141620636},{"id":"https://openalex.org/C109316439","wikidata":"https://www.wikidata.org/wiki/Q246181","display_name":"Cytotoxicity","level":3,"score":0.43083661794662476},{"id":"https://openalex.org/C2780868878","wikidata":"https://www.wikidata.org/wiki/Q1660197","display_name":"Immunogenicity","level":3,"score":0.4279497265815735},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.3784472346305847},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.3508091866970062},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.34613627195358276},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3076722025871277},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.23038652539253235},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.1693272888660431},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.1427919864654541},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.14225560426712036},{"id":"https://openalex.org/C3020616263","wikidata":"https://www.wikidata.org/wiki/Q1216998","display_name":"Tumor cells","level":2,"score":0.11746418476104736}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.sabcs20-ps17-11","doi":"https://doi.org/10.1158/1538-7445.sabcs20-ps17-11","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs20-ps17-11","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3112347154","https://openalex.org/W3094976805","https://openalex.org/W3180038610","https://openalex.org/W3088857581","https://openalex.org/W3082458287","https://openalex.org/W4200193838","https://openalex.org/W4362459740","https://openalex.org/W4298121561","https://openalex.org/W4282982885","https://openalex.org/W3088648667"],"abstract_inverted_index":{"Abstract":[0],"Background":[1],"TCEs":[2,156,499],"are":[3,98,506],"effective":[4,170,193],"at":[5,114,272,295,345,352,363,401,414,419,468,484],"inducing":[6],"remissions":[7],"in":[8,15,67,126,150,225,230,238,246,267,307,376,392,426,557],"hematologic":[9],"cancers":[10],"but":[11,36,341,354,416],"have":[12,38,147],"been":[13,39,148,334],"challenging":[14],"solid":[16],"tumors":[17,68,174,198],"due":[18,41],"to":[19,24,42,72,100,168,191,208,280,298,314,338,366,487],"on-target,":[20],"off-tumor":[21],"toxicity.":[22],"Attempts":[23],"circumvent":[25],"CRS":[26,410,474],"include":[27],"fractionated":[28],"or":[29,55,152],"step-up":[30],"dosing":[31,313],"and/or":[32,44],"complex":[33],"molecular":[34],"designs,":[35],"these":[37],"unsuccessful":[40],"toxicity":[43,362],"enhanced":[45],"immunogenicity.":[46],"Amunix":[47],"has":[48,333],"developed":[49],"a":[50,131,136,179,184,443,458,476,501,544],"conditionally":[51],"active":[52],"TCE,":[53],"XPAT":[54,498],"XTENylated":[56],"Protease-Activated":[57],"bispecific":[58],"T-Cell":[59],"Engager,":[60],"that":[61,103],"exploits":[62],"the":[63,74,81,101,115,118,127,142,166,189,210,393,449,497,574],"protease":[64,324],"activity":[65,211,224,467],"present":[66],"vs.":[69],"healthy":[70],"tissue":[71,361],"expand":[73],"therapeutic":[75],"index":[76],"(TI).":[77],"The":[78],"core":[79,102],"of":[80,85,117,124,161,212,259,285,370,382,395,446,466,573],"HER2-XPAT":[82,277,302,332,347,371,422,456],"(PAT)":[83],"consists":[84],"2":[86],"tandem":[87],"scFVs":[88],"targeting":[89],"CD3":[90],"and":[91,108,139,199,217,233,236,253,257,289,360,372,411,438,442,475,514,555],"HER2.":[92,176],"Two":[93],"unstructured":[94],"polypeptide":[95],"masks":[96,120],"(XTEN)":[97],"attached":[99],"sterically":[104],"reduce":[105],"target":[106],"engagement":[107],"extend":[109],"T1/2.":[110],"Protease":[111],"cleavage":[112,325,381],"sites":[113],"base":[116],"XTEN":[119],"enable":[121],"proteolytic":[122],"activation":[123,256,554],"XPATs":[125],"tumor":[128,180,287,305,309,323],"microenvironment,":[129],"unleashing":[130],"highly":[132],"potent":[133,245,459,552],"TCE":[134],"with":[135,183,311,385,423,463],"short":[137],"T1/2":[138],"further":[140],"improving":[141],"TI.":[143],"Although":[144],"checkpoint":[145],"inhibitors":[146],"ineffective":[149],"HER2+":[151],"HR+":[153,439],"breast":[154],"cancer,":[155],"can":[157],"co-opt":[158],"T-cells":[159],"regardless":[160],"their":[162],"antigenic":[163],"specificity,":[164],"providing":[165,421],"potential":[167,190],"introduce":[169],"T-cell":[171,194,249,255,328,350,461],"immunity":[172],"against":[173,196,283,293],"expressing":[175],"HER2-XPAT,":[177,213],"as":[178],"protease-activatable":[181,546],"prodrug":[182,460,547],"wide":[185,478],"safety":[186,237,447,563],"margin,":[187],"offers":[188],"induce":[192],"cytotoxicity":[195,250,266,292,434],"HER2hi":[197],"HR+/HER2":[200],"1-2+":[201],"tumors.":[202],"Methods":[203],"Preclinical":[204],"studies":[205,505],"were":[206,374],"conducted":[207],"characterize":[209],"HER2-PAT":[214,241,263,407],"(cleaved":[215,242],"XPAT),":[216],"HER2-NonClv":[218,318,373],"(a":[219],"non-cleavable":[220,317],"XPAT)":[221,243],"for":[222,227,234,327,398,436,452],"cytolytic":[223],"vitro,":[226],"anti-tumor":[228],"efficacy":[229,515,556],"xenograft":[231],"models,":[232],"stability":[235,389],"NHPs.":[239],"Results":[240],"demonstrated":[244,348],"vitro":[247],"tumor-directed":[248],"(EC50":[251,275],"1-2pM)":[252],"target-dependent":[254],"production":[258],"cytokines":[260],"by":[261,404],"PBMCs.":[262],"also":[264],"exhibited":[265,290],"HR+,":[268],"HER2":[269,286,437],"1+":[270],"MCF7s":[271],"higher":[273],"doses":[274,364,470,485],"0.13nM).":[276],"provided":[278],"up":[279,297,337,365,486],"14,000-fold":[281],"protection":[282,425],"killing":[284],"cells":[288],"no":[291,320],"cardiomyocytes":[294],"concentrations":[296],"1uM.":[299],"In":[300,330],"vivo,":[301],"induced":[303,408],"complete":[304],"regressions":[306],"BT-474":[308],"models":[310],"equimolar":[312],"HER2-PAT,":[315,430],"whereas":[316],"had":[319],"efficacy,":[321],"supporting":[322],"requirement":[326],"activity.":[329,454],"NHP,":[331,377],"dose-escalated":[335],"safely":[336],"42mg/kg":[339],"(MTD)":[340],"was":[342,417],"not":[343],"tolerated":[344,418,427],"50mg/kg.":[346],"early":[349],"margination":[351],"2mg/kg":[353],"largely":[355],"spared":[356],"CRS,":[357],"cytokine":[358,412],"production,":[359],"42mg/kg.":[367,488],"PK":[368],"profiles":[369],"comparable":[375],"indicating":[378],"minimal":[379,473],"systemic":[380],"XPAT,":[383],"consistent":[384],"its":[386],"ex":[387],"vivo":[388],"when":[390],"incubated":[391],"plasma":[394],"cancer":[396],"pts":[397],"7":[399],"days":[400],"37\u00b0C.":[402],"Given":[403],"continuous":[405],"infusion,":[406],"lethal":[409],"spikes":[413],"0.3mg/kg/d,":[415],"0.2mg/kg/d,":[420],">3000-fold":[424],"Cmax":[428],"versus":[429],">4":[431],"logs":[432],"over":[433,448],"EC50s":[435],"cell":[440],"lines,":[441],"20-fold":[444],"margin":[445],"dose":[450],"required":[451],"pharmacodynamic":[453],"Conclusions":[455],"is":[457],"engager":[462,549],"promising":[464,502],"evidence":[465],"low":[469,495],"while":[471],"exhibiting":[472],"potentially":[477],"TI":[479],"based":[480,565],"on":[481,566],"NHP":[482],"tolerability":[483],"With":[489],"XTEN\u2019s":[490],"prior":[491],"clinical":[492],"data":[493,516],"demonstrating":[494],"immunogenicity,":[496],"provide":[500],"solution.":[503],"IND":[504],"currently":[507],"ongoing.":[508],"Additional":[509],"PK,":[510],"PD,":[511],"cytokines,":[512],"safety,":[513],"will":[517],"be":[518],"presented.":[519],"Citation":[520],"Format:":[521],"Fiore":[522],"Cattaruzza,":[523],"Ayesha":[524],"Nazeer,":[525],"Zachary":[526],"Lange,":[527],"Caitlin":[528],"Koski,":[529],"Mikhail":[530],"Hammond,":[531],"Angela":[532],"Henkensiefken,":[533],"Trang":[534],"Dao-Pick,":[535],"Mika":[536],"K":[537],"Derynck,":[538],"Bryan":[539],"Irving,":[540],"Volker":[541],"Schellenberger.":[542],"Her2-xpat,":[543],"novel":[545],"t-cell":[548,553],"(tce),":[550],"exhibits":[551],"her2":[558],"tumors,":[559],"yielding":[560],"large":[561],"predicted":[562],"margins":[564],"non-human":[567],"primate":[568],"(nhp)":[569],"[abstract].":[570],"In:":[571],"Proceedings":[572],"2020":[575,582],"San":[576,585],"Antonio":[577],"Breast":[578],"Cancer":[579,591],"Virtual":[580],"Symposium;":[581],"Dec":[583],"8-11;":[584],"Antonio,":[586],"TX.":[587],"Philadelphia":[588],"(PA):":[589],"AACR;":[590],"Res":[592],"2021;81(4":[593],"Suppl):Abstract":[594],"nr":[595],"PS17-11.":[596]},"counts_by_year":[{"year":2023,"cited_by_count":1}],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2021-03-01T00:00:00"}